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Abstract
Background: The REGENT-VSEL trial demonstrated a neutral effect of transendocardial injection 
of autologous bone marrow (BM)-derived CD133+ in regard to myocardial ischemia. The current 
sub-analysis of the REGENT-VSEL trial aims to assess the effect stem cell therapy has on quality of life 
(QoL) in patients with refractory angina.
Methods: Thirty-one patients (63.0 ± 6.4 years, 70% male) with recurrent CCS II–IV angina, despite 
optimal medical therapy, enrolled in the REGENT-VSEL single center, randomized, double-blinded, 
and placebo-controlled trial. Of the 31 patients, 16 individuals were randomly assigned to the active 
stem cell group and 15 individuals were randomly assigned to the placebo group on a 1:1 basis. The 
inducibility of ischemia, (≥ one myocardial segment) was confirmed for each patient using Tc-99m 
SPECT. QoL was measured using the Seattle Angina Questionnaire. Each patient completed the ques-
tionnaire prior to treatment and at the time of their outpatient follow-up visits at 1, 4, 6, and 12 months 
after cell/placebo treatment.
Results: The main finding of the REGENT-VSEL trial sub-analysis was that transendocardial in-
jection of autologous BM-derived CD133+ stem cells in patients with chronic refractory angina did 
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Introduction
Advances in the surgical, interventional and 
pharmacological treatment of patients with acute 
coronary syndromes have improved long-term 
clinical outcomes including quality of life (QoL). 
Moreover, novel therapeutic strategies are ben-
eficial for patients with stable coronary artery 
disease (CAD) and large myocardial ischemic 
burden [1–3]. Nevertheless, as a consequence 
of an aging population, the number of individuals 
with severe coronary atherosclerosis not amend-
able for conventional revascularization continues 
to increase [4]. In many patients, despite optimal 
medical therapy, chronic myocardial ischemia is 
associated with debilitating anginal pain, which ad-
versely influences  QoL. Persistent ischemic chest 
discomfort is related to a higher rehospitalization 
rate [5], mortality and morbidity [6, 7]. Transendo-
cardial delivery of autologous and allogeneic stem/
progenitor cells is a promising alternative treatment 
option for patients diagnosed with refractory angina. 
Noteworthly, Rodrigo et al. [8] have also indicated 
an important economic aspect that this therapy is 
proving to reduce system resources of healthcare 
utilization. However, previously published data 
showed inconsistent results in regard to stem cell 
effectiveness. Studies with unselected mononuclear 
cells demonstrated a beneficial impact on angina 
symptoms and improvement of myocardial perfu-
sion [9–11]. Conversely, the PROGENITOR trial 
enrolling refractory angina patients, who underwent 
transendocardial CD133+ cells injection, did not 
confirm previous observations [12]. Thus, additional 
studies are needed to evaluate and establish an op-
timal treatment strategy. In addition, factors such 
as patient selection criteria, cell types and route of 
administration should all be taken into consideration. 
In the present study, QoL and the severity of 
chest pain in no-option angina patients treated with 
transendocardial autologous bone marrow-derived 
CD133+ cells were evaluated as the REGENT-
-VSEL trial sub-analysis (NCT01660581, www.
clinicaltrials.gov) [13].
Methods
REGENT-VSEL, a single center, randomized, 
double-blinded, placebo-controlled study, was 
coordinated by an independent Clinical Research 
Organization (www.kcri.pl), which provided 
a randomization system using sealed envelopes. 
Randomization was performed in the hematology 
center before cell/placebo processing on 1:1 basis. 
The study protocol and baseline characteristics 
are described in the previous publication [13]. 
Briefly, patients with refractory angina pectoris 
despite optimal medical therapy and were disqual-
ified from further revascularization procedures 
were enrolled in the study.
Inclusion criteria
Inclusion criteria were as follows: 1) stable 
angina in Canadian Cardiovascular Society (CCS) 
II–IV class despite maximum pharmacotherapy 
for at least 2 weeks since the prior medication 
change; 2) presence of ≥ 1 myocardial segment with 
reversible ischemia in qualifying Tc-99m single 
photon emission computed tomography (SPECT); 
3) disqualified from further revascularization by an 
independent Heart Team; 4) age > 18 and < 75 
years and 5) written informed consent. 
Exclusion criteria
Exclusion criteria were as follows: 1) acute 
coronary syndrome ≤ 6 months; 2) heart failure 
New York Heart Association (NYHA) III–IV class; 
3) left ventricular (LV) ejection fraction (LVEF) 
< 35%; 4) contraindications to NOGA procedure 
(ventricular wall thickness < 8 mm, intracardiac 
thrombus, severe aortic stenosis, LV an aneurysm 
or severe peripheral artery disease precluding 
vascular access); 5) previous implantation of car-
dioverter-defibrillator or pacemaker; 6) history of 
malignancy; 7) active infection; 8) life expectancy 
less than 6 months; 9) bleeding diathesis; 10) re-
nal insufficiency (GFR < 30 mL/min/1.73 m2) and 
11) pregnancy, lactation, or lack of adequate contra-
ception in women of childbearing potential. After 
not show significant improvement in QoL in comparison to the control group. Moreover, there was no 
significant difference between cell therapy and placebo in a number of patients showing improvement of 
at least 1 Canadian Cardiovascular Society class during the follow-up period.
Conclusions: Intra-myocardial delivery of autologous CD133+ stem cells is safe and feasible but does 
not show a significant improvement in the QoL or angina pectoris symptoms in patients with chronic 
myocardial ischemia. (Cardiol J 2018; 25, 4: 521–529)
Key words: quality of life, refractory angina, bone marrow, cell therapy, CD133 cells
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providing informed consent patients underwent 
baseline SPECT and magnetic resonance imaging.
End-points
Based on the REGENT-VSEL trial, the follow-
ing end-points were evaluated in this sub-analysis: 
QoL and change in the angina severity (CCS class) 
assessed at baseline and during outpatient follow-
up visits at 1, 4, 6, 12 months after cell/placebo 
application.
Endocardial mapping  
and intramyocardial injection
NOGA-XP 3D electro-mechanical system 
(Biosense Webster, Johnson&Johnson, Diamond 
Bar, CA, USA) was applied for endocardial mapping 
(200–250 valid points collected) and intramyocardi-
al application. In the active group, patients received 
autologous CD133+ bone marrow (BM)-derived 
stem cells (mean number of 3.2 ± 2.4 × 106). In 
the placebo group, patients received 0.9% NaCl 
with the addition of 10% donor serum. The region 
of interest was determined based on NOGA-XP 
electromechanical parameters defining hibernating 
areas (an abnormal mechanical function with viable 
myocardium). A median of 10 trans-endocardial 
cell/placebo injections (200 µL per application) 
were performed with a comparable mean volume 
in both groups. 
Clinical status and QoL assessment
During hospitalization and scheduled outpa-
tient follow-up visits at 1, 4, 6, 12 months after 
cell/placebo delivery: (1) severity of angina was 
assessed according to the CCS scoring system, 
grading chest pain symptoms from I to IV and 
(2) QoL as measured using the Seattle Angina 
Questionnaire (SAQ) ranging from 0% to 100% 
[14]. The SAQ quantifies five categories: physi-
cal limitation (PL), angina stability (AS), angina 
frequency (AF), treatment satisfaction (TS) and 
quality of life score (QOLs).
Participant treatment allocations were dou-
ble-blinded during hospitalization and during the 
whole follow-up period. Moreover, the principal 
investigator was blinded in regard to QoL ques-
tionnaires filled out by patients during outpatient 
clinic visits. 
The REGENT-VSEL study was approved by 
the Ethics Committee of the Medical University 
of Silesia in Katowice and Office for Registration 
of Medicinal Products, Medical Devices, and Bioc-
idal Products. The trial is in accordance with the 
Declaration of Helsinki. 
Statistical analysis 
Categorical variables were presented as num-
bers and percentages. Continuous variables were 
expressed as the mean ± standard deviation (SD) 
or median and interquartile range (IQR). Differ-
ences between groups were compared using the 
Student or Welch t-test depending on equality of 
variances for normally distributed variables. The 
Mann-Whitney U test was used for non-normally 
distributed continuous variables and ordinal data. 
The Shapiro-Wilk test assessed normal distribution 
of variables. Equality of variances was assessed 
using the Levene test. P values < 0.05 were con-
sidered statistically significant. All calculations 
were done with JMP®, Version 13.1.0 SAS Institute 
Inc., Cary, NC.
Results
Out of 90 patients screened, 31 individuals 
(63.0 ± 6.4 years, 70% male) were enrolled in the 
study and were randomly assigned to an active 
treatment group receiving CD133+ cells (n = 16) 
or placebo group (n = 15). There were no sig-
nificant differences in the distribution of baseline 
characteristics and pharmacotherapy between the 
study groups (Table 1). 
The occurrence of peri-procedural serious 
adverse events (SAE) was noted in 2 patients 
allocated to the active group: (1) acute back pain 
in the lumbar area radiating to the abdomen dur-
ing the mapping procedure, which was related to 
previously diagnosed spondyloarthritis and was 
fully resolved after analgesic treatment, (2) pseu-
doaneurysm of the femoral artery.
Clinical parameters
Clinical assessment was carried out at baseline 
and after 1, 4, 6 and 12 months in an outpatient 
setting.
There were no cases of death or of myocardial 
infarction (MI) noted during outpatient follow-up 
visits. Two SAEs occurred in the placebo-treated 
group, (unstable angina: treated medically; deep 
vein thrombosis) and one SAE in the active group 
which was a hospital admission for unstable angina 
and was treated conservatively.
Repeated measure analysis of CCS changes 
within groups showed no significant differences: 
p = 0.63 and p = 0.32 in stem cell and placebo 
group, respectively (Fig. 1A, B). Overall differences 
across the repeated measures of CCS in the total 
population was observed (p = 0.04), but did not 
vary across study groups (p = 0.38).
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In comparison to the placebo group, QOLs 
improved 1 month after stem cell therapy (60.42 ± 
± 19.12 vs. 44.44 ± 19.84, p = 0.05, respectively). 
However, there was no significant difference meas-
ured after 4 months (55.36 ± 23.02 vs. 49.40 ± 
± 22.52, p = 0.81, respectively), 6 months (60.71 ± 
± 25.20 vs. 55.45 ± 25.08, p = 0.64, respectively) 
and 12 months (63.33 ± 21.55 vs. 53.06 ± 21.04, 
p = 0.26, respectively) (Fig. 2). Furthermore, there 
was a statistically significant inter-group difference 
in QOLs at month 1 and 4 (p = 0.04) — QOLs 
improved in the placebo group with no change in 
treatment (Table 2).
One-year evaluation of PL, AS, AF and TS 
showed similar results between the two groups. 
Table 3 shows PL score measured during consecu-
tive follow-up visits. In comparison to baseline, PL 
increased in both control and treatment groups 
throughout the first year of follow-up. A statisti-
cally significant difference was observed between 
month 1 and 6 (p = 0.03). The PL score decreased 
in the treatment group but improved in the placebo 
group. There was no difference detected between 
the two groups in the AS and AF scores (Table 4 and 
Table 5, respectively). Analysis of TS, presented in 
Table 6, showed a statistically non-significant trend 
towards inter-group difference between month 1 
and 4 as well as between month 1 and 6 post stem 
cell/placebo treatment.
Discussion
In accordance with previously published stud-
ies, the REGENT-VSEL trial showed that intra-
myocardial application of autologous stem cells is 
safe and feasible [9–11, 15]. However, the main 
finding of the present sub-analysis is that trans-
endocardial application of autologous BM-derived 
CD133+ stem cells in patients with chronic re-
fractory angina did not show significant improve-
ment in the QoL and CCS class within 12 month 
follow-up. Similarly, in the PROGENITOR trial [12] 
Table 1. Baseline characteristics of study groups.
Placebo group (n = 15) Active group (n = 16) P
Age [years] 61.7 ± 5.4 64.2 ± 7.2 0.28
Man 11 (73.3%) 12 (75.0%) > 0.99
Cardiovascular risk factors:
Smoking (current or past) 6 (40%) 10 (62.5%) 0.29
Hypertension 13 (86.7%) 15 (93.7%) 0.60
Diabetes 8 (53.3%) 4 (25%) 0.15
Chronic kidney disease 2 (13.3%) 1 (6.2%) 0.60
Dyslipidemia 14 (93.3%) 15 (93.7%) > 0.99
Family history of CAD 5 (33.3%) 8 (50%) 0.47
Chronic medications:
ASA 15 (100%) 16 (100%) –
Clopidogrel 6 (40%) 6 (37.5%) > 0.99
ACEI 12 (80%) 13 (81.2%) > 0.99
ARB 3 (20%) 3 (18.7%) > 0.99
Statins 15 (100%) 16 (100%) –
CCB 7 (46.7%) 5 (31.2%) 0.47
Beta-blockers 14 (93.3%) 15 (93.7%) > 0.99
Nitrates 4 (26.7%) 10 (62.5%) 0.07
Diuretics 10 (66.7%) 6 (37.5%) 0.15
Medical history:
Prior myocardial infarction 11 (73.3%) 10 (62.5%) 0.70
Prior CABG 12 (80%) 13 (81.2%) > 0.99
Prior PCI 10 (66.67%) 12 (75%) 0.70 
ASA — acetylsalicylic acid; ACEI — angiotensin converting enzyme inhibitor; ARB — angiotensin II receptor blocker; CABG — coronary artery 
bypass grafting; CAD — coronary artery disease; CCB — calcium channel blockers; PCI — percutaneous coronary intervention
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peripheral blood (PB)-derived immuno-selected 
CD133+ cells were applied showing no improve-
ment in regard to QoL and angina symptoms. On 
the contrary, the ACT34-CMI [9] and RENEW 
[16] trials suggest the clinical applicability of 
intramyocardially injected 1 × 105 / 5 × 105 and 
1 × 105 – 1 × 107 selected CD34+ cells, respec-
tively. Interestingly, in the ACT34-CMI study, 
a lower dose (1 × 105 cells) was associated with 
significant and persistent improvement in angina 
symptoms at 2-year follow-up.
Previously published trials with refractory 
angina patients treated with BM- and PB-derived 
mononuclear cells (MNC) produced promising 
overall results. The vast majority of studies pre-
sented a reduction of angina frequency in short- and 
long-term (5 years) follow-up [10, 11, 15, 17–21]. 
In the RE-INJECT AP trial [17], NOGA-based 
intramyocardial application of 100 × 106 BM-
MNC was performed improving QoL and CCS 
class with increased myocardial perfusion during 
the first and second (after 4.6 ± 2.5 years) cell 
Figure 1. Mosaic plot representing Canadian Cardiovascular Society (CCS) changes during 12-month follow-up (FU) 
in stem cell group (A) and placebo group (B). 
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injections. Moreover, Rodrigo et al. [18] observed 
similar clinical effects in patients who had had pla-
cebo injections in the past, and who had received 
100 × 106 of MNC during the trial. Interestingly, in 
the REGENT-VSEL and RE-INJECT AP trials, no 
increase in LVEF was observed. On the contrary, 
patients enrolled in the PROTECT-CAD, who 
received low (1 × 106) or high (2 × 106) dose of 
MNC showed an increase of LVEF [10] with CCS 
reduction in the active and placebo group. Moreo-
ver, in studies by Beers et al. [19] (84 ± 20 × 106 
of bone marrow-derived mononuclear cells [BMC], 
trans-endocardial), Mathiasen et al. [20] (21.5 × 106 
of mesenchymal stromal cells, trans-endocardial) 
and Lasala et al. [21] (7.5 × 106 of BMC/MNC, 
intracoronary) demonstrated positive impact on 
angina symptoms and was associated with improve-
ment in LV function. Distinct effect of unselected 
Table 3. Seattle Angina Questionnaire — physical limitation (PL) category.
Difference of PL between Placebo group  
(n = 15)





12M FU and baseline 13.89 (–8.33;26.39) 2.78 (–2.78;13.89) 8.33 (–2.78;19.10) 0.58
6M FU and baseline 8.33 (–1.39;16.67) 5.56 (–4.86;11.11) 5.56 (–2.78;14.58) 0.42
4M FU and baseline 1.39 (–5.56;12.50) 2.78 (2.08;14.58) 2.78 (–1.39;14.24) 0.35
1M FU and baseline 0.00 (0.00;5.42) 2.78 (0.00;9.38) 0.00 (0.00;8.33) 0.09
12M FU and 1M FU 13.89 (–9.03;23.61) 0.00 (–8.33;5.56) 2.78 (–8.33;18.75) 0.17
6M FU and 1M FU 8.33 (–4.17;16.67) –1.39 (–11.18;2.78) 2.78 (–8.33;11.11) 0.03
4M FU and 1M FU 2.78 (–4.17;10.56) 0.00 (–6.94;8.33) 0.00 (–5.56;8.33) 0.50
12M FU and 4M FU 2.78 (–4.17;15.28) 0.00 (–8.33;8.33) 1.39 (–6.25;12.85) 0.29
6M FU and 4M FU 5.56 (–5.56;14.58) 0.00 (–8.33;2.78) 0.00 (–8.33;8.33) 0.28
12M FU and 6M FU 0.00 (–6.94;8.33) 0.00 (–2.08;6.94) 0.00 (–5.56;6.25) 0.66
Data presented as median (Q1;Q3); FU — follow-up; M — months
Table 2. Seattle Angina Questionnaire — quality of life score (QOLs).
Difference in QOLs between Placebo group  
(n = 15)





12M FU and baseline 8.33 (–8.33;25.00) 8.33 (–8.33;25.00) 8.33 (–8.33;25.00) 0.87
6M FU and baseline 8.33 (–8.33;25.00) 0.00 (–8.33;16.67) 0.00 (–8.33;16.67) 0.48
4M FU and baseline 0.00 (–10.42;10.42) 0.00 (–8.33;0.00) 0.00 (–8.33;8.33) 0.33
1M FU and baseline 0.00 (–8.33;8.33) 4.17 (0.00;8.33) 0.00 (0.00;8.33) 0.20
12M FU and 1M FU 8.33 (–8.33;33.33) 0.00 (–8.33;16.67) 4.17 (–8.33;18.75) 0.62
6M FU and 1M FU 8.33 (–4.17;20.83) 0.00 (–8.33;2.08) 0.00 (–8.33;16.67) 0.06
4M FU and 1M FU 0.00 (–2.08;12.50) 0.00 (–16.67;0.00) 0.00 (–8.33;6.25) 0.04
12 FU and 4M FU  –4.17 (–8.33;12.50) 0.00 (–4.17;20.83) 0.00 (–8.33;16.67) 0.20
6M FU and 4M FU 0.00 (–4.17;20.83) 0.00 (0.00;16.67) 0.00 (0.00;16.67) 0.72
12M FU and 6M FU –8.33 (–16.67;4.17) 0.00 (–4.17;8.33) 0.00 (–8.33;8.33) 0.11
Data presented as median (Q1;Q3); FU — follow-up; M — months
Figure 2. Quality of life scores at baseline and follow-up 
(FU) visits. 
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Table 4. Seattle Angina Questionnaire — angina stability (AS) category.
Difference of AS between Placebo group  
(n = 15)





12M FU and baseline 0.00 (–25.00;50.00) 0.00 (0.00;25.00) 0.00 (0.00;31.25) 0.93
6M FU and baseline 0.00 (–12.50;37.50) 0.00 (0.00;25.00) 0.00 (0.00;25.00) 0.94
4M FU and baseline 0.00 (0.00;31.25) 0.00 (–6.25;25.00) 0.00 (0.00;25.00) 0.64
1M FU and baseline 0.00 (0.00;25.00) 0.00 (0.00;25.00) 0.00 (0.00;25.00) 0.91
12M FU and 1M FU 0.00 (–25.00;25.00) 0.00 (0.00;25.00) 0.00 (–25.00;25.00) 0.70
6M FU and 1M FU 0.00 (–37.50;25.00) 0.00 (–6.25;6.25) 0.00 (–25.00;25.00) 0.82
4M FU and 1M FU 0.00 (–25.00;25.00) 0.00 (–6.25;6.25) 0.00 (–18.75;25.00) 0.85
12M FU and 4M FU 0.00 (–6.25;0.00) 0.00 (–12.50;12.50) 0.00 (0.00;0.00) 0.78
6M FU and 4M FU 0.00 (–25.00;12.50) 0.00 (0.00;0.00) 0.00 (0.00;0.00) 0.62
12M FU and 6M FU 0.00 (0.00;0.00) 0.00 (–25.00;0.00) 0.00 (0.00;0.00) 0.33
Data presented as median (Q1;Q3); FU — follow-up; M — months
Table 5. Seattle Angina Questionnaire — angina frequency (AF) category.
Difference of AF between Placebo group  
(n = 15)





12M FU and baseline 10.00 (0.00;20.00) 10.00 (0.00;30.00) 10.00 (0.00;22.50) 0.80
6M FU and baseline 0.00 (0.00;10.00) 10.00 (–20.00;20.00) 0.00 (0.00;20.00) 0.73
4M FU and baseline 10.00 (0.00;10.00) 0.00 (–10.00;20.00) 0.00 (0.00;10.00) 0.43
1M FU and baseline 0.00 (0.00;10.00) 5.00 (0.00;20.00) 0.00 (0.00;20.00) 0.17
12M FU and 1M FU 10.00 (0.00;20.00) 10.00 (0.00;10.00) 10.00 (0.00;20.00) 0.54
6M FU and 1M FU 0.00 (0.00;15.00) 0.00 (–20.00;12.50) 0.00 (0.00;10.00) 0.37
4M FU and 1M FU 0.00 (–2.50;10.00) 0.00 (–20.00;0.00) 0.00 (–10.00;0.00) 0.15
12M FU and 4M FU 0.00 (–2.50;12.50) 10.00 (0.00;15.00) 0.00 (0.00;10.00) 0.20
6M FU and 4M FU 0.00 (–5.00;0.00) 0.00 (–5.00;20.00) 0.00 (0.00;0.00) 0.79
12M FU and 6M FU 0.00 (0.00;10.00) 10.00 (0.00;20.00) 0.00 (0.00;10.00) 0.33
Data presented as median (Q1;Q3); FU — follow-up; M — months
Table 6. Seattle Angina Questionnaire — treatment satisfaction (TS) category.
Difference in TS between Placebo group  
(n = 15)





12M FU and baseline 12.50 (0.00;18.75) 0.00 (0.00;18.75) 3.13 (0.00;18.75) 0.97
6M FU and baseline 18.75 (0.00;25.00) 0.00 (0.00;6.25) 6.25 (0.00;18.75) 0.10
4M FU and baseline 0.00 (0.00;18.75) 0.00 (–6.25;6.25) 0.00 (–4.69;10.94) 0.17
1M FU and baseline 0.00 (0.00;6.25) 3.13 (0.00;10.94) 0.00 (0.00;6.25) 0.43
12M FU and 1M FU 0.00 (0.00;12.50) 0.00 (–6.25;12.50) 0.00 (–6.25;12.50) 0.60
6M FU and 1M FU 12.50 (0.00;21.88) 0.00 (–6.25;1.56) 0.00 (–6.25;12.50) 0.05
4M FU and 1M FU 0.00 (0.00;12.50) 0.00 (–1.56;0.00) 0.00 (0.00;4.69) 0.06
12M FU and 4M FU 0.00 (–3.13;7.81) 0.00 (–6.25;18.75) 0.00 (–6.25;12.50) 0.58
6M FU and 4M FU 0.00 (–6.25;12.50) 0.00 (–6.25;7.81) 0.00 (–6.25;6.25) 0.63
12M FU and 6M FU 0.00 (–12.50;6.25) 0.00 (–3.13;18.75) 0.00 (–7.81;12.50) 0.21
Data presented as median (Q1;Q3); FU — follow-up; M — months 
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MNC on myocardium may be associated with the 
heterogeneity of the injected cell population.
Currently, there is no evidence to support the 
use of immune-selected cells (CXCR4 or CD133) 
over non-selected BM-MNC in patients with 
stable CAD or MI. In the IMPACT-CABG [22] 
and CARDIO133 [23] trials, CD133/CD34/CD45 
triple-positive, and CD133+ cells, respectively, 
were injected transepicardially during a coronary 
artery bypass grafting procedure showing no 
advantage over placebo in patients with ischemic 
cardiomyopathy. On the contrary, Stamm et al. [24] 
used CD133+ cells in the same group of patients 
and reported improved perfusion with a significant 
increase in LVEF at 3-year follow-up. Interestingly, 
intracoronary delivery of autologous BM-derived 
CD133+/CD34+ cells in patients with ischemic 
heart diseases and a history of MI (3–6 months 
before enrolment), proved to have a beneficial 
effect on myocardium by improving perfusion 
and reducing the scar area [25]. Furthermore, the 
clinical applicability of intracoronary delivered 
immune-selected cells was evaluated in patients 
with recent MI showing improved LV function 
[26, 27]. On the contrary, those results were not 
confirmed in the TIME trial including ST-segment 
elevation MI patients treated with percutaneous 
coronary intervention and subsequent intracoro-
nary administration of unselected BM-MNC [28].
As presented above, the results of published 
studies are incoherent. Thus, it is crucial to deter-
mine the characteristics of patients who respond 
to cell therapy. According to individual SPECT 
analysis from the REGENT-VSEL and a study by 
Rodrigo et al. [29], patients with a higher number 
of abnormal perfusion segments at baseline tended 
to have more significant improvement after cell 
application. Multivariate analysis indicates that 
allocation to an active group increased the chance 
of positive response to cell treatment by 3.5-times, 
and with a  history of MI by 1.5-times. Moreover, 
diabetes was also associated with a significant 
response to BMC therapy [29].
The presented data suggests that application 
of immuno-selected CD133 cells is not optimal for 
angina symptom treatment in patients with chronic 
myocardial ischemia. 
Limitations of the study
Since the study was stopped prematurely due 
to slow patient enrollment, it  may be considered 
underpowered. Thus, sub-analysis results should 
be interpreted with caution.
Conclusions
Findings support the feasibility and safety 
of transendocardial injection of CD133+ cells in 
patients with refractory angina. The present study 
waslimited by a low number of patients and did not 
demonstrate a significant improvement in QoL or 
angina pectoris symptoms in patients receiving 
cell therapy.
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